APRIL HUGGLER: Open Payments
NPI 1265092449 · FREEHOLD, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,271 in 81 payments from 17 companies in 2025. Trend: 2023 $1,363 · 2024 $1,307 · 2025 $1,271
Food & beverage: $1,271
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $224 |
| Novo Nordisk Inc | 10 | $175 |
| PFIZER INC. | 10 | $152 |
| AstraZeneca Pharmaceuticals LP | 9 | $145 |
| Lilly USA, LLC | 8 | $136 |
| Dexcom, Inc. | 3 | $65 |
| GlaxoSmithKline, LLC. | 4 | $64 |
| Currax Pharmaceuticals LLC | 4 | $61 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $52 |
| Exact Sciences Corporation | 2 | $47 |
Products named: ZEPBOUND, VRAYLAR, PREVNAR 20, UBRELVY, FARXIGA, Wegovy, Dexcom G6 Transmitter, TRELEGY ELLIPTA.
Industry payments across NJ — which companies pay providers there.
